Idera Pharmaceuticals downgraded by JP Morgan
$IDRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan downgraded Idera Pharmaceuticals from Overweight to Neutral
Save time and jump to the most important pieces.
4 - Aceragen, Inc. (0000861838) (Issuer)
4 - Aceragen, Inc. (0000861838) (Issuer)
4 - Aceragen, Inc. (0000861838) (Issuer)
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. ("Aceragen," the "Company," "we," "us," or "our") and "ACGN". Additionally, the Company's stockholders approved the conversion into common s
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. "We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases," stated John Taylor, Idera's Chief Executive Officer. "Our resulting cash position is expected to provide runway into Q3 2023 and fund the advancement of our pipeline, including ACG-701 and ACG-801, through important anticipated 2023 clinical
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
SC 13D/A - Aceragen, Inc. (0000861838) (Subject)
Wedbush downgraded Idera Pharma from Outperform to Neutral and set a new price target of $1.00 from $8.00 previously
Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously
JMP Securities downgraded Idera Pharmaceuticals from Outperform to Market Perform
Gainers Sotera Health Company (NASDAQ:SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached agreements to settle the Ethylene Oxide cases pending against Sterigenics. Sterigenics will pay the company $408 million to settle the claims. Party City Holdco Inc. (NYSE:PRTY) gained 54% to $0.3193 following an Axios report suggesting The Franchise Group could be looking at acquiring the company. Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares rose 51.1% to $0.1224 after gaining 4% on Monday. VYNE Therapeutics Inc. (NASDAQ:VYNE) climbed 50.5% to $0.2892 after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201
Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE Therapeutics's trading volume reached 2.9 million shares. This is 590.3% of its average volume over the last 100 days. The company's market cap stands at $20.8 million. Clearside Biomedical (NASDAQ:CLSD) stock increased by 12.41% to $1.81. The market value of their outstanding shares is at $108.9 million. Nuwellis (NASDAQ:NUWE) shares increased by 12.01% to $10.44. Nuwellis's trading volume hit 230.9K shares by close, accounting for 92.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.5 million. First Wave BioPhar
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme
EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we are eagerly anticipating objective response rate and other important data from ILLUMINATE-301, our pivotal registration trial in anti-PD-1 refractory advanced melanoma, later this month,” stated Vincent Milano, Idera’s Chief Executive Officer. “I’m very proud of our team’s resiliency and tenacity as they work diligently toward that goal, as well as the ongoing work in ILLUMINATE-206,
15-12G - Aceragen, Inc. (0000861838) (Filer)
EFFECT - Aceragen, Inc. (0000861838) (Filer)
EFFECT - Aceragen, Inc. (0000861838) (Filer)